Project will use microfluidic technology to improve efficiency of peptide therapeutics discovery for challenging drug target Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded  a Smart grant by Innovate UK, the […]

Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi […]

Orbit Discovery will be attending BIO in San Diego between the 13th and 17th June 2022. If you wish to hear more about our unique peptide discovery service platform, functional screening capabilities and cell based screening we will be delighted to arrange a meeting with our CEO, Dr Neil Butt and CTO, Anthony Pitt. We […]

Orbit Discovery will be attending the TIDES between the 9th and 13th May 2022. If you wish to hear more about our unique peptide discovery service platform, functional screening capabilities and cell based screening we will be delighted to arrange a meeting with our CEO, Dr Neil Butt and CTO, Anthony Pitt.